Figure 3.
Sequence of normalization of laboratory, clinical, and lymph node responses in siltuximab responders. Responders were those achieving durable tumor (radiologic) and symptomatic responses (n = 18).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.